HEPATOCELLULAR CARCINOMA

This trial investigates whether giving two immunotherapy drugs, ipilimumab and nivolumab, before liver surgery can help shrink tumors in people with liver cancer (hepatocellular carcinoma). Participants receive the drugs in the weeks leading up to their planned surgery. The study…

This phase 2 trial tested whether adding an experimental drug called SRF388 to a standard two-drug regimen (atezolizumab plus bevacizumab) helps people with advanced liver cancer that hasn't been treated before. The study enrolled 30 adults whose cancer could not be surgically re…

This completed trial tested whether a daily EPA (an omega-3 fatty acid) supplement could help preserve muscle mass and reduce inflammation in 18 people with advanced liver cancer that could not be surgically removed. Participants took either the EPA supplement or a placebo for 12…

This completed phase 4 trial tested whether adding SB Flavon (a blend of flavonoids, vitamin C, and L-arginine) to standard Tenofovir therapy can reverse advanced liver scarring (cirrhosis) and prevent liver cancer in 134 people with chronic hepatitis B. The study measured liver …

This study tested a combination of two drugs (atezolizumab and bevacizumab) given before surgery to people with liver cancer. The goal was to see how well the drugs shrink the tumor and how they affect the immune system. 40 participants were enrolled, and researchers also studied…

This study tested a combination of chemotherapy infused into the liver artery plus two drugs (camrelizumab and apatinib) in 21 people with liver cancer that could not be surgically removed. The goal was to shrink the tumors enough to allow surgery. The study is complete, and resu…

This early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…

This study tested whether adding an experimental drug (CCR2/5-inhibitor or anti-IL-8) to the immunotherapy nivolumab before and after surgery could help shrink tumors and improve long-term survival in people with non-small cell lung cancer or liver cancer. 48 participants receive…

This study tested a combination of Y90 radioembolization (a targeted radiation treatment for the liver) and nivolumab (an immunotherapy drug) in 40 Asian patients with advanced liver cancer that could not be surgically removed. The goal was to see if the combination could shrink …

This early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…

This study tested whether giving radiotherapy to liver cancer patients with limited tumor growth (oligo progression) could delay the need for second-line drug therapy. Thirty-six adults with advanced hepatocellular carcinoma received targeted radiation. The goal was to see if thi…

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…

This large phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) can prevent liver cancer from coming back in people who had successful surgery or ablation. 959 participants received either pembrolizumab or a placebo every three weeks. The study measured ho…

This study tested a combination of proton beam radiotherapy followed by two drugs (Tecentriq and Avastin) in 63 adults with advanced liver cancer that had spread into the portal vein. The goal was to see if this approach could help control the cancer and improve survival. Partici…

This study tested a triple combination treatment for advanced liver cancer that has spread. It combines a procedure called TACE (which blocks blood flow to the tumor) with immunotherapy drugs (PD-1/PD-L1 inhibitors) and targeted therapies (VEGF-TKI or bevacizumab). The goal is to…

This study tested a three-pronged approach for intermediate-stage liver cancer: a procedure that blocks blood flow to the tumor (TACE), immunotherapy drugs that help the immune system fight cancer, and targeted drugs that stop blood vessel growth. Over 900 patients participated. …

This study tested a new treatment for advanced liver cancer that has spread into the major blood vessels of the liver. Thirty patients received a special type of radiation along with an immunotherapy drug called tislelizumab. The goal was to see if this combination could help pat…

This study tested a new way to destroy small liver tumors using two microwave antennas at once, compared to the standard single antenna method. Twenty patients with small hepatocellular carcinoma (liver cancer) were treated. The goal was to see if the two-antenna approach could m…

This study tested whether interferon-free drug combinations can cure hepatitis C in 150 people who had been successfully treated for liver cancer. Participants took pills like sofosbuvir and ribavirin for 12 weeks. The main goal was to see if the virus stayed undetectable 12 week…

This study tested a special type of radiofrequency ablation using two cooled needles that also release saline to treat liver cancer that came back after chemoembolization. The goal was to see if this technique could better destroy the tumor and prevent it from growing back. One h…

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This phase 3 trial tested whether adding radiofrequency ablation (RFA) to standard transarterial chemoembolization (TACE) improves outcomes for people with intermediate-stage liver cancer. 241 participants with 2-10 liver tumors were randomly assigned to receive either TACE alone…

This study tested a procedure called selective internal radiation therapy (SIRT) using Y-90 resin microspheres (SIR-Spheres) in one patient with liver cancer that could not be removed by surgery. The goal was to see if a flexible dosing approach could improve outcomes like tumor …

This study tested a new combination of two drugs (IBI310 and sintilimab) against the standard drug sorafenib for people with advanced liver cancer who had not received prior treatment. The goal was to see if the combination could help patients live longer or shrink tumors more ef…

This small pilot study tested a combination of two drugs, alectinib and nivolumab, in 5 adults with advanced liver cancer that had not responded to standard treatments. The goal was to see if the combination could shrink tumors. Because it was a very early phase 1 trial with very…

This study tested a high-precision radiation treatment called stereotaxic radiotherapy (CyberKnife) in 44 adults with a single liver cancer tumor. The goal was to stop the tumor from growing for at least 18 months. Participants received three high-dose radiation sessions over 8-1…

This phase II trial tested a drug called AK112 in 40 people with advanced liver cancer that could not be removed by surgery. AK112 is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth. The study measured safety and how well the drug shrank …

This study tested a combination of an immunotherapy drug (durvalumab) and chemotherapy delivered directly to the liver (HAIC) in 30 adults with advanced liver cancer that had spread into the main portal vein. The goal was to see if the combination could improve one-year survival.…

This study tested a combination of two drugs, SHR-1210 (an immunotherapy) and apatinib (a targeted therapy), in 190 adults with advanced liver cancer that did not respond to or could not tolerate prior treatment. The goal was to see if the combination could shrink tumors and cont…

This early-stage trial tested whether combining donafinib (a targeted therapy) with an anti-PD-1 antibody (an immunotherapy) can safely prevent liver cancer from coming back after surgery. It involved 30 patients with high-risk features like microvascular invasion or multiple tum…

This early-phase study tests two experimental drugs, BI 765049 and ezabenlimab, in adults with advanced solid tumors like colorectal, lung, and pancreatic cancer. The main goal is to find the highest safe dose of BI 765049 alone and in combination with ezabenlimab. Participants r…

This study tested a three-drug combination for people with advanced liver cancer that has spread into the portal vein (a major blood vessel). The treatment adds a liver-directed chemotherapy infusion to two standard drugs (lenvatinib and a PD-1 inhibitor). The goal was to see if …

This early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…

This study looked at liver cancer patients whose tumors shrank completely after non-surgical treatments like chemoembolization and immunotherapy. Researchers compared those who then had surgery to remove any remaining tissue versus those who simply watched and waited. The goal wa…

This study tested a combination of two drugs, relatlimab and nivolumab, in 266 adults with advanced liver cancer who had not received immunotherapy before but whose cancer worsened after other treatments. The goal was to see if the combination could shrink tumors or control the d…

This study tested a new way to make radiation therapy more effective for people with liver cancer. Doctors used special ultrasound contrast agents (tiny gas-filled microbubbles) and then 'popped' them with ultrasound waves to make tumors more sensitive to radiation. The study inv…

This phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.

This study tested two immunotherapy drugs, nivolumab and ipilimumab, in people with advanced liver cancer that could not be treated with surgery. The goal was to see if these drugs could shrink tumors and control the disease. The trial included 657 adults and found that the treat…

This phase 2 trial tested a combination of two drugs—telatinib (a pill that blocks tumor blood vessels) and Keytruda (an immunotherapy that helps the immune system attack cancer)—in 16 people with advanced stomach, gastroesophageal junction, or liver cancer. The goal was to see i…

This study looked at 562 people with advanced liver cancer to compare two treatment combinations: one using HAIC (chemotherapy directly into the liver) plus immunotherapy and targeted drugs, and the other using TACE (a procedure that blocks blood flow to the tumor) plus the same …

This early-stage study tested a new drug called BAT1308 in 59 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body. Th…

This study looked at how safe the drug cabozantinib is for people with advanced liver cancer (hepatocellular carcinoma) who have already tried another treatment called sorafenib. A total of 110 adults took part. The main goal was to see how long patients lived after starting cabo…

This phase 2 trial tested whether adding rivoceranib to camrelizumab after surgery or ablation helps prevent liver cancer from coming back in high-risk patients. 251 participants were randomly assigned to receive either the combination or camrelizumab alone. The main goal was to …

This study tested giving the cancer drug nivolumab as a shot under the skin (instead of through an IV) to people with advanced cancers like lung, kidney, melanoma, liver, and colorectal cancer. The main goal was to see how the drug moves in the body and to check for side effects.…

This early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…

This study tested two chemotherapy drugs, cisplatin and mitomycin-C, given directly into the liver artery for people with liver cancer that cannot be surgically removed. The goal was to see how long tumors stay controlled and to track side effects. 76 participants were enrolled. …

This study tested whether a 6-day infusion of somatostatin, a drug that lowers pressure in the liver's blood vessels, could prevent ascites (fluid buildup) after liver cancer surgery. 179 patients with liver cancer and underlying liver disease took part. The goal was to see if so…

This study tested a new drug called SAR444245 combined with other cancer treatments in 138 adults with advanced gastrointestinal cancers, including esophageal, stomach, liver, and colorectal cancer. The goal was to see if the combination could shrink tumors. The study is complete…

This study tested a new way to deliver chemo directly to liver tumors using a wrist artery instead of the groin. Thirty-eight patients with liver cancer took part. The goal was to see if the wrist approach is safe, feasible, and effective, with fewer complications and faster reco…

This study looked at 639 adults with cirrhosis to see if a blood test called mSEPT9 can detect liver cancer (hepatocellular carcinoma) better than the current standard test (AFP). Participants gave an extra blood sample during routine care, and researchers compared how well each …

This study tested a new ultrasound technique (Side-by-Side Contrast-Enhanced Ultrasound) to see if it could accurately check whether microwave ablation fully destroyed liver tumors just 1-3 days after treatment. Researchers compared it to standard contrast-enhanced ultrasound in …

This study tested a new artificial intelligence (AI) algorithm against the standard LI-RADS criteria for diagnosing liver cancer (hepatocellular carcinoma) on CT scans. Researchers enrolled 300 people at risk for liver cancer who had a new liver nodule found on ultrasound. The go…

This study looked at blood samples from 573 people to find new markers that could diagnose liver cancer more accurately. Researchers compared samples from patients with liver cancer, those with other liver conditions, and people with hepatitis infections. The goal is to improve u…

This study looked at whether a breath test could help detect liver fibrosis, cirrhosis, or liver cancer. Researchers collected breath samples from 56 patients with known or suspected liver disease and analyzed them for specific chemical markers. The goal was to see if the test co…

This study looked at whether measuring tiny molecules called microRNAs in the blood can help diagnose liver cancer (hepatocellular carcinoma) in people with hepatitis C. Researchers tested blood samples from 84 participants, including healthy people and those with hepatitis C, wi…

This study tested a new radioactive tracer called [18F]FAPI-74 for PET scans in people with gastrointestinal cancers, including liver, bile duct, stomach, pancreatic, and colorectal cancers. The goal was to see if the tracer can accurately detect cancer cells by comparing scan re…

This study tested a special PET/MRI scan that uses a radioactive tracer to find liver cancer cells. The goal was to see if this scan can detect liver cancer earlier and more accurately than standard scans. 52 adults with liver cancer took part, and researchers compared the new sc…

This study looked at whether mindfulness exercises can lower stress and improve communication between patients with liver disease and their doctors. 56 adults took part, answering surveys about their stress, anxiety, and how well they felt they could share decisions with their he…

This study tested two approaches to bring palliative care (comfort-focused care) to people with end-stage liver disease. About 1,500 adults from 19 U.S. centers took part. One group had direct access to a palliative care specialist; the other group saw a liver doctor specially tr…

This completed study looked at a new antibody called anti-SIRPα as a potential immunotherapy for liver cancer. Researchers used blood and tissue samples from 30 liver cancer patients to see how the antibody affects immune cells. The goal was to understand whether blocking the SIR…

This completed study looked at 3000 patients having liver surgery to see if considering both medical and social factors could reduce how long they stay in the hospital. Researchers tracked things like complications and readmissions. The goal is to find ways to improve recovery an…

This study looked at 180 people with liver cancer (hepatocellular carcinoma) who also had cirrhosis caused by either fatty liver disease or alcohol use. Researchers compared immune cells and gut bacteria in the liver to understand why cancer develops. The goal was to gather knowl…

This study followed 326 adults in Zambia with chronic hepatitis B for up to 5 years. Researchers tracked how the virus behaves, how many patients need treatment, and how many develop serious liver problems like cirrhosis or liver cancer. The goal was to better understand the dise…

This study looked at 10 people with liver cancer (HCC) who were getting a standard treatment called chemoembolization (c-TACE). The goal was to see if mixing the chemotherapy drug doxorubicin with salt water or a contrast dye changes how the drug spreads inside the tumor. Researc…

This study tracked 295 adults who had high-risk surgery for stomach, esophagus, pancreas, or liver cancer. Researchers measured quality of life before surgery and again at 6 and 12 months after. They also asked patients and their family members if they regretted the decision to h…

This study looked at how safe and effective a combination of two drugs (Atezolizumab and Bevacizumab) is for people with liver cancer and cirrhosis, compared to standard pills (tyrosine kinase inhibitors). Researchers followed 38 patients to see how long they lived and how their …

This study looked at whether liver cancer spreads differently in men and women. Researchers analyzed data from over 19,000 patients and used computer models to create separate prediction tools for each gender. The goal was to better understand risk factors for cancer spread at th…

This completed study used artificial intelligence to examine CT scans from 274 liver cancer patients who had already received radiation therapy. The goal was to find the radiation dose that causes a visible liver reaction, which could help doctors avoid liver injury in future tre…

This study looked for proteins in the blood that might predict how well liver cancer treatments work. Researchers took blood samples from 17 patients before and after standard treatments like TACE or ablation. The goal was to find biomarkers that could help doctors choose the bes…

This completed study looked at the genetic makeup of liver cancer in 808 patients to better understand the disease. Researchers analyzed tumor samples from people treated with surgery, ablation, or transplant, as well as those with advanced cancer. The goal was to identify key ge…

This study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer pr…

This study looked at 379 people with liver cancer to see if monitoring changes in blood markers over time could help doctors better predict how the disease will progress. Researchers combined these marker trends with patient information to build a more accurate risk model. The go…

This study reviewed medical records of 300 liver cancer patients treated in Brazil between 2017 and 2022. Researchers aimed to understand patient characteristics, how the cancer was managed, and survival outcomes. No new treatments were tested; instead, the goal was to gather rea…

This study tested the EchoTip AcuCore, a needle used during endoscopic ultrasound to collect tissue samples from the pancreas, liver, and other organs. 183 adults with conditions like cancer or chronic pancreatitis took part. The main goal was to see if the needle could get a goo…

This completed study analyzed tumor and blood samples from 166 people with advanced liver cancer who received a combination of atezolizumab and bevacizumab. The goal was to find biomarkers—biological clues—that could predict how well a patient responds to treatment and how long t…